Nyhet -

The world’s first clinically proven AI-assisted gut health solutions

Enbiosis has tamed the challenges of understanding and mapping the complexity of the human gut microbiome.

Using AI, medical researchers and data scientists at Enbiosis have worked closely together to develop an algorithm that can decode one of the most complex systems in the world, the microbiome. By doing so, it is then possible to turn the collected data into a detailed and personalised health report, complete with personalised solutions for each patient.

“The solutions we present include personalised food and pre- & probiotic suggestions. Enbiosis is the first company in the world to develop AI-assisted personalised gut health solutions. This means that we are not only testing the bacteria in the gut, but also analysing them using the most advanced AI-technology and turning the collected data into scores that can be used to map out the entire gut microbiome”, says Yusra Serdaroglu, Head of Nutrition at Enbiosis.

“This is so much more than a generic stool or microbiome test”, she continues. “We are not just scanning the levels of some of the bacteria – we are analysing the entire gut eco-system”.

Personalised Solution

Enbiosis has clinically proven the efficacy of the solutions and has published the results in prestigious journals across the world. The journals include themes such as IBS and chronic constipation, conditions which 15 percent of people in the world suffers from.

“Our AI-assisted gut health solutions are backed up by scientific proof collected through clinical trials. On top of that, we provide completely personalised solutions. This is why we can say that we are first in the field, using AI-assisted methods to improve gut health”, says Yusra Serdaroglu.

Enbiosis has developed an extraordinary solution. Does that mean that it must be expensive?

“Not at all. We provide a personalised health report with 15 different indexes, and a risk analysis of several diseases. This gives the patient a good start to develop a better and healthier lifestyle. Just by adopting a new way of living and eating can decrease the likelihood of developing certain diseases. We also provide a report of more than 300 foods, scored between 0 -10, based on the personal gut microbiome”, Yusra Serdaroglu explains.

“In addition, we provide a list of prebiotics and probiotics that fit the specific microbiome eco-system of each patient”.

Why Medicon Valley?

There are several companies in the Medicon Valley region focusing on the microbiome. This makes the region very appealing to Enbiosis. The headquarters are in the UK. All research and development activities behind the technology have been carried out in Turkey. The core markets are initially UK and the US.

Relaterade länkar

Ämnen

  • Ekonomi, finans

Kategorier

  • medicon valley life science

Regioner

  • Skåne

Kontakter

Relaterat innehåll

  • Brice Group – one of the leading Nordic recruitment and interim providers within Life Science and Health

    In the Öresund region there are approximately 200 Companies and 40.000 employees in the Life Science sector1. Attracting and retaining the right talents are one of the major challenges for the organisations. For the Life Science industry, not being able to identify, attract and retain the right expertise is often one of the greatest pitfalls, potentially jeopardizing entire projects that has taken

  • The best starting point to explore Lund

    The presence of the ever-expanding Medicon Village, Ideon Science Park, Lund University and the university hospital makes Lund an important meeting place for medical researchers from all over the world. A great place to meet up and to stay is the Radisson Blu hotel, just a short walk from both Ideon Science Park and the city centre.

  • Why we initiated the Medicon Valley Alliance Microbiome Network

    Research and development about the role of the microbiome for human health is on the rise. From a European perspective the Medicon Valley region was a first mover, and, consequently, Medicon Valley Alliance and several member companies and stakeholders including the Technical University of Denmark, Lund University, University of Copenhagen and Novo Nordisk decided to both test the interest and adv

  • Fast-growing RCO with high ambitions

    ProPharma is the world’s first Research Consulting Organisation, RCO. With a global perspective, ProPharma offers a new degree of personalization and agility. The new RCO delivers a “3-D printed” solution for those sponsor programs and a personalized approach to drug and device development outsourcing.

  • The go-to option for histological support in drug development queries

    Medetect is a full-service contract research organisation (CRO) within histology with unique competence in immunopathology, computerised quantitative image analysis and histological research. The company has successfully contributed to crucial histology-based research in a vast number of projects in the pharmaceutical industry over the last 15 years.

  • Yazen makes the treatment of obesity more accessible

    Obesity is becoming more and more recognised worldwide as a chronic disease with severe complications ranging from possible to likely. The Swedish healthcare provider Yazen applies a comprehensive approach to the treatment of obesity, and most importantly they are making it more available, accessible and affordable.